<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238146</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02536</org_study_id>
    <secondary_id>OSU-10040</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <secondary_id>CDR0000687197</secondary_id>
    <nct_id>NCT01238146</nct_id>
  </id_info>
  <brief_title>Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I/II Trial of Rituximab, Bendamustine, and Obatoclax in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial is studying the side effects and the best dose of obatoclax mesylate&#xD;
      when given together with rituximab and bendamustine hydrochloride to see how well it works&#xD;
      compared with rituximab and bendamustine hydrochloride alone in treating patients with&#xD;
      relapsed or refractory non-Hodgkin lymphoma. Obatoclax mesylate may stop the growth of cancer&#xD;
      cells by blocking some of the proteins needed for cell growth. Monoclonal antibodies, such as&#xD;
      rituximab, can block cancer growth in different ways. Some find cancer cells and help kill&#xD;
      them or carry cancer-killing substances to them. Others interfere with the ability of cancer&#xD;
      cells to grow and spread. Drugs used in chemotherapy, such as bendamustine hydrochloride,&#xD;
      also work in different ways to stop the growth of cancer cells, either by killing the cells&#xD;
      or by stopping them from dividing. Giving obatoclax mesylate together with rituximab and&#xD;
      bendamustine hydrochloride may kill more cancer cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of the&#xD;
      combination of obatoclax mesylate, rituximab, and bendamustine hydrochloride in patients with&#xD;
      relapsed or refractory, indolent, B-cell non-Hodgkin lymphoma (phase I).&#xD;
&#xD;
      II. To define the qualitative and quantitative toxicities of the combination of obatoclax&#xD;
      mesylate, rituximab, and bendamustine (phase I).&#xD;
&#xD;
      III. To detect an improvement in median progression-free survival (PFS) from 6 to 12 months&#xD;
      with the addition of obatoclax mesylate to rituximab and bendamustine hydrochloride in&#xD;
      patients with indolent B-cell non-Hodgkin lymphoma (phase II).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the overall objective response rate to the combination of obatoclax mesylate,&#xD;
      rituximab, and bendamustine versus rituximab and bendamustine hydrochloride in patients with&#xD;
      relapsed or refractory, indolent, B-cell non-Hodgkin lymphoma.&#xD;
&#xD;
      II. To characterize two-year PFS of patients with indolent B-cell non-Hodgkin lymphoma&#xD;
      receiving obatoclax mesylate, rituximab, and bendamustine hydrochloride versus rituximab and&#xD;
      bendamustine hydrochloride.&#xD;
&#xD;
      III. To assess the pharmacokinetics of obatoclax mesylate in patients with relapsed or&#xD;
      refractory, indolent, B-cell non-Hodgkin lymphoma.&#xD;
&#xD;
      IV. To assess the pharmacokinetics of the combination of bendamustine hydrochloride and&#xD;
      obatoclax mesylate in patients with relapsed or refractory, indolent, B-cell non-Hodgkin&#xD;
      lymphoma.&#xD;
&#xD;
      V. To determine the effects of the combination of rituximab, bendamustine hydrochloride, and&#xD;
      obatoclax mesylate on histone-oligodeoxynucleotide (ODNA) and levels of activated Bax and Bak&#xD;
      pro-apoptotic proteins in peripheral blood mononuclear cells and bone marrow aspirate&#xD;
      specimens.&#xD;
&#xD;
      VI. To identify associations of genetic polymorphisms in drug-metabolizing enzymes,&#xD;
      transporters, or target genes with pharmacokinetics, pharmacodynamics, or clinical outcomes.&#xD;
&#xD;
      OUTLINE: This is a phase I, dose-escalation study of obatoclax mesylate followed by a&#xD;
      randomized phase II study.&#xD;
&#xD;
      PHASE I: Patients receive obatoclax mesylate IV over 3 hours on days 1-3, rituximab IV over&#xD;
      4-8 hours on day 1 (day 3 of course 1), and bendamustine hydrochloride IV over 30 minutes on&#xD;
      day 1-2 (day 2-3 of course 1). Treatment repeats every 28 days for a maximum of 6 courses in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PHASE II: Patients are stratified according to prior bendamustine hydrochloride (yes vs no).&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      ARM I: Patients receive obatoclax mesylate IV over 3 hours on days 1-3, rituximab IV over 4-8&#xD;
      hours on day 1, and bendamustine hydrochloride IV over 30 minutes on days 1-2.&#xD;
&#xD;
      ARM II: Patients receive rituximab and bendamustine hydrochloride as in arm I.&#xD;
&#xD;
      In both arms, treatment repeats every 28 days for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo blood and bone marrow sample collection at baseline and periodically during&#xD;
      study for pharmacokinetics, pharmacodynamic, and pharmacogenetic studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 3 months for 2 years and&#xD;
      then every 6 months for 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patients accrued.&#xD;
  </why_stopped>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerable dose, defined as the dose level beneath which 2 or more of 6 patients experience DLT (phase I)</measure>
    <time_frame>28 days</time_frame>
    <description>Graded using CTCAE version 4 criteria. DLTs are defined as grade 3-4 neutropenia or thrombocytopenia that persists beyond day 42; grade 4 febrile neutropenia or infection; grade 3 febrile neutropenia or infection that fails to resolve within 7days, grade 3-4 somnolence, ataxia, or confusion that requires inpatient admission on day 1 for observation and prevents patient discharge from outpatient clinic, or other grade 3-4 non-hematologic toxicity excluding infection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in median progression-free survival (PFS) (phase II)</measure>
    <time_frame>From 6 to 12 months</time_frame>
    <description>Estimated using the method of Kaplan-Meier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall objective response rate (phase II)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>95% confidence intervals will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (phase II)</measure>
    <time_frame>From the date of start of therapy to disease progression or death, whichever occurs first, assessed at 2 years</time_frame>
    <description>Estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue</condition>
  <condition>Nodal Marginal Zone B-cell Lymphoma</condition>
  <condition>Recurrent Grade 1 Follicular Lymphoma</condition>
  <condition>Recurrent Grade 2 Follicular Lymphoma</condition>
  <condition>Recurrent Mantle Cell Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Splenic Marginal Zone Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive obatoclax mesylate IV over 3 hours on days 1-3, rituximab IV over 4-8 hours on day 1, and bendamustine hydrochloride IV over 30 minutes on days 1-2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive rituximab and bendamustine hydrochloride as in arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>bendamustin hydrochloride</other_name>
    <other_name>bendamustine</other_name>
    <other_name>cytostasan hydrochloride</other_name>
    <other_name>Treanda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>obatoclax mesylate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>GX15-070MS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 monoclonal antibody</other_name>
    <other_name>Mabthera</other_name>
    <other_name>MOAB IDEC-C2B8</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed indolent B-cell non-Hodgkin lymphoma (NHL), including any of&#xD;
             the following subtypes recognized by WHO classification:&#xD;
&#xD;
               -  Marginal zone lymphoma&#xD;
&#xD;
               -  Lymphoplasmacytic lymphoma&#xD;
&#xD;
               -  Follicular lymphoma&#xD;
&#xD;
               -  Mantle cell lymphoma&#xD;
&#xD;
          -  Transformed lymphoma from a low-grade, indolent NHL allowed provided patient has&#xD;
             received ≥ 1 prior therapy for indolent disease&#xD;
&#xD;
          -  Must have received ≥ 1 prior therapy&#xD;
&#xD;
          -  Relapsed disease after autologous or allogeneic stem cell transplantation (SCT)&#xD;
             allowed (phase I)&#xD;
&#xD;
               -  No relapse after allogeneic SCT (phase II)&#xD;
&#xD;
          -  No known CNS lymphoma&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  ANC ≥ 1,000/µL&#xD;
&#xD;
          -  Platelet count ≥ 50,000/µL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception prior to and for the duration of&#xD;
             study participation&#xD;
&#xD;
          -  No active hepatitis B infection&#xD;
&#xD;
               -  Patients with a history of hepatitis B (surface antigen or core antibody&#xD;
                  positive) must take lamivudine or equivalent during study therapy&#xD;
&#xD;
          -  No history of documented human anti-globulin antibodies, or a history of allergic&#xD;
             reactions attributed to compounds of similar chemical or biologic composition to&#xD;
             rituximab, bendamustine hydrochloride, or obatoclax mesylate&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness and/or social situations that would limit compliance with&#xD;
                  study requirements&#xD;
&#xD;
          -  HIV infection allowed provided patient meets the following criteria:&#xD;
&#xD;
               -  No evidence of co-infection with hepatitis B or C&#xD;
&#xD;
               -  CD4 cell count ≥ 400/mm³&#xD;
&#xD;
               -  No evidence of resistant strains of HIV&#xD;
&#xD;
               -  HIV viral load ≤ 10,000 copies HIV RNA/mL for patients not on anti-HIV&#xD;
                  combination antiretroviral therapy OR HIV viral load ≤ 50,000 copies HIV RNA/mL&#xD;
                  for patients on anti-HIV therapy&#xD;
&#xD;
               -  No history of AIDS-defining conditions&#xD;
&#xD;
          -  No active secondary malignancy except for non-melanomatous skin cancer&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  Prior bendamustine hydrochloride allowed provided patient has completed a&#xD;
             bendamustine-containing regimen within the past 6 months and achieved a partial&#xD;
             response or better&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas&#xD;
             or mitomycin C) and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Christian</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2010</study_first_posted>
  <last_update_submitted>June 5, 2013</last_update_submitted>
  <last_update_submitted_qc>June 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Obatoclax</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

